false 0001870144 0001870144 2023-12-05 2023-12-05 0001870144 CDIO:CommonStockParValue0.00001Member 2023-12-05 2023-12-05 0001870144 CDIO:RedeemableWarrantsEachWarrantExercisableForOnehalfOfOneShareOfCommonStockMember 2023-12-05 2023-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

   

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

December 6, 2023  (December 5, 2023)

Date of Report (Date of earliest event reported)

 

CARDIO DIAGNOSTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41097   87-0925574
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

311 W. Superior Street, Suite 400, Chicago, IL   60654
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:  (855) 266-9991

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.00001   CDIO   The Nasdaq Stock Market LLC
Redeemable warrants, each warrant exercisable for one share of common stock   CDIOW   The Nasdaq Stock Market LLC

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 
 
Item 8.01 Other Events

As previously reported, on September 21, 2023, Cardio Diagnostics Holdings, Inc. (the “Company”) received a written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the closing bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and that, as a result, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The Company was provided 180 calendar days, until March 19, 2024, to regain compliance.

On December 5, 2023, the Company received written notice from the Listing Qualifications Staff of Nasdaq notifying the Company that, for the last 10 consecutive business days, from November 20, 2023 through December 4, 2023, the closing bid price of the Company’s common stock was $1.00 per share or greater. Accordingly, the written notice stated that the Company has regained compliance with the minimum bid price listing requirement set forth under the Rule.

On December 6, 2023, the Company issued a press release announcing that it regained compliance with Nasdaq Listing Rule 5550(a)(2) and that Nasdaq has closed this matter.

Item 9.01 Financial Statements and Exhibits.
Exhibit  Description
99.1  

Press Release Dated December 6, 2023

104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  December 6, 2023 CARDIO DIAGNOSTICS HOLDINGS INC.
   
   By: /s/ Elisa Luqman
    Elisa Luqman
Chief Financial Officer